ClinicalTrials.gg
Not yet recruitingNCT07777705transplantUpdated Aug 20, 2026

Application of Different Scores in Predicting Outcomes of Cirrhotic Patients Awaiting Liver Transplantation

An observational study in Liver Cirrhosis and Liver Transplant, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
153
Ages
18 Years to 60 Years
Sex
All
01

Study summary

the goal of this observational study is to apply different scores 1. To assess Fatigue, Frailty, Liver Transplant Comorbidity Index and MELD 3.0 in patients with liver cirrhosis awaiting liver transplantation.

2. To evaluate the predictive accuracy of these Scores for the short-term outcomes (early complications, recurrent hospitalization and 3-month mortality). 3. To determine whether using these Scores in the pre-transplant evaluation improves risk stratification compared to MELD score alone.

Read the detailed description

c. Sample Size Calculation: Sample size was calculated using Epi Info 7. According to the results of a previous study (put ref.), frailty was detected in 17% of patients undergoing liver transplantation. Based on this percentage, with a confidence limit of 5%, a confidence level of 90%, and a design effect of 1, the estimated sample size required is approximately 153 patients.

All patients recruited in the current study will be subjected to the following:

  1. Detailed history taking such as age, sex, duration of disease, etiology of liver cirrhosis, endoscopic history, complications, previous hospitalization and indication for liver transplantation.
  2. Laboratory investigations: CBC (Complete Blood Count), Liver Function Test, Kidney Function test, Serum Electrolytes levels (Sodium, Potassium and Calcium).
  3. Calculation of - Child Pugh score . Figure (I) Child Pugh score

    • MELD score = 10 x (0.957 x Ln (serum creatinine mg/dl) + 0.378 x Ln (serum bilirubin mg/dl) + 1.120 x Ln (INR) + 0.643).
    • MELD-Na score = MELD + 1.59 x (135 - Na) with maximum and minimum Na of 135 and 120 mmol/l, respectively.
    • MELD 3.0 = 1.33 if female+4.56 * loge(bilirubin) + 0.82*137 - Na- 0.24* 137 - Na *loge(bilirubin) + 9.09*loge (INR) + 11.14*loge(creatinine) + 1.85*3.5 - albumin- 1.83*3.5 -albumin *loge(creatinine) +6

      4) Anthropometric measurement:

      1. Weight in Kilograms (Kg).
      2. Height in Meters (m).
      3. Body Mass Index in (kg/m2): BMI was calculated as weight (kilograms) divided by height squared (meters) in kg/ m2 with normal range in adult between 18.5 - 24.9 kg/m2 .
      4. Waist Circumference in Centimeters (cm).
      5. Mid-arm circumference in Centimeters (cm).

        5) Fatigue Severity Assessment (via FSS and BFI):

        • Fatigue Severity Scale (FSS) (1 = strongly disagree, 7 = strongly agree).
        • Brief Fatigue Inventory (BFI) (Rating from 0-10).

I) Fatigue Severity Scale (FSS):

The FSS is a 9-item scale designed to assess the severity of fatigue and its impact on daily activities. Here are the items:

  1. I am easily fatigued.
  2. Fatigue interferes with my physical functioning.
  3. Fatigue causes frequent problems for me.
  4. Fatigue interferes with my ability to work, study, or engage in social activities.
  5. Fatigue interferes with my family life.
  6. Fatigue interferes with my leisure activities.
  7. When I am fatigued, I have difficulty concentrating.
  8. Fatigue is a problem for me.
  9. Fatigue interferes with my ability to maintain a regular exercise program. Scale will be from 9-63. Scale up to 35: no fatigue. Scales >35: severe fatigue.

II) Brief Fatigue Inventory (BFI):

The BFI includes 3 questions on fatigue severity and 6 on how fatigue interferes with daily activities. Here are the items:

Fatigue Severity:

  1. How would you rate your fatigue right now?
  2. How would you rate your usual fatigue over the past 24 hours?
  3. How would you rate your worst fatigue over the past 24 hours?

    Interference with Daily Activities:

  4. Fatigue interferes with general activity.
  5. Fatigue interferes with mood.
  6. Fatigue interferes with walking ability.
  7. Fatigue interferes with normal work (including housework).
  8. Fatigue interferes with relations with other people.
  9. Fatigue interferes with enjoyment of life.

6) Liver Transplant Comorbidity Index: This index includes the following components and their respective points Factor Points Coronary artery disease 6 Frailty (LFI more than 4.5) 5 HCC 5 Cr more than 1.0mg/dl or on dialysis 3 Diabetes 1

Total score = sum of points.

  • Low risk: Few or no factors → \~93% 3 year survival.
  • Moderate risk: Intermediate score → \~87% 3 year survival.
  • High risk: Multiple factors → \~80% 3 year survival.

7) Liver frailty index (LFI): The Liver Frailty Index (LFI) is the most widely validated frailty assessment tool in LT. It integrates three performance-based measures: handgrip strength, the Five-Times Sit-to-Stand Test (5xSST), and balance testing, to generate a continuous score that categorizes patients as robust, prefrail, or frail. The LFI has been shown to independently predict waitlist mortality, hospitalization, and delisting, even after adjustment for MELD score

A) Handgrip strength:

Handgrip strength is measured using a calibrated handheld dynamometer. Three measurements are obtained from the dominant hand, and the maximum value (in kilograms) is used for scoring. Grip strength reflects global muscle strength and correlates closely with sarcopenia and adverse clinical outcomes in patients with Cirrhosis.

B) Five-times sit-to-stand test (5xSST):

The Five-Times Sit-to-Stand Test, also referred to as chair-stand time, is a standardized, performance-based measure of lower extremity muscle strength, power, and functional mobility. The test is simple, rapid, and requires no specialized equipment, making it particularly well suited for use in patients with chronic liver disease and LT candidates. The 5xSST is performed as follows: the patient is seated upright in a chair; on command, the patient stands up fully and then sits down completely; this cycle is repeated five times as quickly as possible. The total time is recorded in seconds.

C) Balance testing:

Balance testing evaluates postural stability and neuromuscular coordination, which are frequently impaired in patients with cirrhosis due to sarcopenia, peripheral neuropathy, and hepatic encephalopathy. Within the LFI, balance is assessed using three hierarchical standing positions that are performed sequentially and held for up to 10 s each.

The three components of the LFI are combined using a validated formula: LFI = (0.330 ×sex-adjusted grip strength in kg) + (0.529 × 5xSST in seconds) + (0.040 × balance time in seconds) + 6.

(calculator available at http://liverfrailtyindex.ucsf.edu).

7.Sarcopenia assessment will be done for those prepared for transplantation: Definition of sarcopenia is based on: -

  1. Computed tomography-skeletal muscle index (CT-SMI) with cut-offs of \< 41 cm2/m2 for men and \< 32 cm2/m2 for women
  2. Hand grip strength with cut-offs of \< 27 kg in men and \< 16 kg in women
  3. Bioimpedance analysis-skeletal muscle index (BIA-SMI) with cut-offs of \< 8.87 kg/m2 for men and \< 6.42 kg/m2 for women . According to guideline for European working group on sarcopenia in older people (EWGSOP, the Sarcopenia Working Group) sarcopenia identification was based on both low muscle mass and strength using CT-SMI and hand grip strength

    • Imaging for assessment of Sarcopenia using:

      1. Computed tomography (CT scan):

        The CT scanner differentiated body tissues; organs, adipose, skeletal muscle and bone, water and air based on tissue-specific attenuation values such as SM (-29, +150) and adipose tissue (-190, -30). These attenuation values were reported in Hounsfield Units (HU) named after Sir Godfrey Newbold Hounsfield, the scientist and electrical engineer who invented the CT scanner .The L3 region contains the spinal vertebrae, intestine, kidney and liver, in addition to visceral adipose, subcutaneous adipose and seven muscle groups; the psoas, erector spinae, quadratus lumborum, transversus abdominus, external and internal obliques and rectus abdominus

        Step-by-step Guidelines for analyzing a single cross-sectional image:

        A) Extraction of CT images: The electronic medical record was assessed to determine if the patient of interest had a CT study that included the L3 region during the desired time interval. Once the CT study had been verified, the patient medical record number, CT study type, scan date and storage device (if transporting images) was provided to the radiologist .

        B) Technique for assessment of waist circumference (WC) and skeletal muscle (SM) area Once the L3 image was obtained and determined to be of good quality, the following CT imaging protocol was used for assessment of waist circumference (WC) and skeletal muscle (SM) area at the L3 region.

        Computed tomography-based assessment at the level of the third lumbar vertebra (L3) is widely regarded as the reference standard for quantitative muscle assessment in patients with cirrhosis and LT candidates. CT uses tissue-specific X-ray attenuation values, expressed in Hounsfield units (HU), to distinguish skeletal muscle, adipose tissue, and bone .Commonly used CT-derived metrics include the psoas muscle area (PMA), psoas muscle index (PMI), and skeletal muscle index (SMI), the latter typically expressed as cross-sectional area divided by height squared (cm²/m²)

      2. Abdominal ultrasound (US):

        Abdominal ultrasound examinations were performed with the subject in the supine position using a 3.75-MHz convex Ultrasound probe. After the routine screening for the abdomen, a transverse scan at the right groin area demonstrated a cross-sectional view of the right iliac artery and vein, which was used as the landmark to detect the iliopsoas muscle located outside the vessels . The iliopsoas muscle area was measured by manual tracing on the image. The iliopsoas muscle index (IP index) was determined by the muscle area divided by the square of height (m2) .

      3. Bioimpedance analysis (BIA):

Bioimpedance analysis (BIA) involved passage of a small AC electrical current through the body. As current was conducted by body water, impedance was inversely related to total body water, thus allowing calculation of total muscle mass, which was the largest water-rich tissue in the body .Body composition was assessed with bioimpedance analysis (BIA) using Body Composition Analyzer Fat free mass was measured by BIA and skeletal muscle mass (SMM) was calculated by the following equation: SMM (kg) = 0.566 x FFM (fat free mass) Skeletal muscle mass index (SMMI) was calculated as skeletal muscle mass (kg) /height (m)2.

02

Conditions studied

  • Liver Cirrhosis
  • Liver Transplant

Keywords

  • cirrhosis and transplantation
  • Liver cirrhosis
  • Liver transplantation
03

In context

Liver Cirrhosis

1,298 studies on the registry are indexed under Liver Cirrhosis; 338 are open to participants now.

This study's planned enrollment of 153 is below the median of 171 across 526 observational studies indexed under Liver Cirrhosis.

Browse Liver Cirrhosis studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

cirrhotic patients awaiting transplantation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • All patients with liver cirrhosis (whatever the etiology) eligible for liver transplantation above the age of 18.

      • Written provided.

Exclusion criteria

Exclusion Criteria:

  • Old age (above 60 years old)
  • Acute liver cell failure without underlying cirrhosis
  • Absolute (e.g., uncontrolled sepsis, severe cardiopulmonary dysfunction, active ).
  • Extra-MELD indications (e.g., hepatopulmonary syndrome, ascites, cholestatic pruritus, hepatoblastoma). We restricted our cohort to patients listed for liver transplantation based on MELD-driven indications. This decision was made to reduce heterogeneity and ensure that eligibility determinations were primarily driven by MELD scores, thereby allowing us to isolate the relative contribution of frailty in the context of MELD-based allocation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
153 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Waitlist morbidity and Mortality of liver transplantation

    * Risk of early complications, rehospitalization and death while awaiting transplantation. 2\. Post-Transplant Survival for liver transplant recipients * 3- month survival (short-term outcome). Mortality hazard ratios associated with frailty, comorbidities, and MELD 3.0

    Time frame: 1.5 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • 1) Peng JK, et al: The impact of cirrhosis on health-related quality of life. Liver International, 2019,39(3), 1234-1242. 2) Alberts CJ, Clifford GM, Georges D, et al (2022): Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol;7(8): 724-735. 3) Bodzin AS, Baker TB: Liver transplantation today: where we are now and where we are going. Liver Transplant: Off Publicat American Assoc Stud Liver Diseas Int Liver Transplant Soc 2018;24:1470-5. 4) Terrault NA, Francoz C, Berenguer M, Charlton M, Heimbach J: Liver transplantation 2023: status report, current and future challenges. Clin Gastroenterol Hepatol : Offi Clin Pract J American Gastroenterol Assocn 2023;21: 2150-66. 5) Hughes CB, Humar A: Liver transplantation: current and future. Abdominal Radiol 2021;46:2-8. 6) Sousa Da Silva RX, Weber A, Dutkowski P, Clavien PA: Machine perfusion in liver transplantation. Hepatology (Baltimore, Md) 2022;76:1531-49. 7) Hoare M, Das T, Alexander G: Ageing, telomeres, senescence, and liver injury. J Hepatol 2010;53:950-61. 8) Saiman Y, Serper M: Frailty and sarcopenia in patients pre- and post-liver transplant. Clin Liver Dis 2021;25:35-51. 9) Zaccherini G, Weiss E, Moreau R: Acute-on-chronic liver failure: definitions, pathophysiology and principles of treatment. JHEP Report :Iinnovat Hepatol 2021; 3:100176. 10) Angeli P, Gines P: Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice. J Hepatol 2012;57: 1135-40. 11) Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K: Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant 2014;14:1870-9. 12) Sinclair M, Poltavskiy E, Dodge JL, Lai JC: Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist. World J Gastroenterol 2017;23:899

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.

Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 15 months is below that.

Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2026
First posted
Aug 20, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07777705
Lead sponsor
Assiut University
Responsible party
Noha Ahmed Mohamed Refaat Askalany (Assistant lecturer, Assiut University) — Principal investigator
First posted
Aug 20, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Aug 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion